The investigational clinical pipeline, however, shows a clear trend toward the development of therapeutic antibodies that are more complex. 4–6 In addition to full-length canonical antibodies, the pipeline increasingly includes bi- or multispecific antibodies 7–10 and antibody-drug conjugates (ADCs), 11 as well as antibody fragments, fragment-Fc and appended Ig, which can be naked, conjugated to other molecules or fused to non-Ig proteins, and can have monospecific, bispecific, or multispecific properties.
1
—
—